IngenOx Therapeutics Contributes to Review of Diagnostic Biomarkers for Precision Bowel Cancer Adjuvant Therapy
Oxford, UK – 07 Dec 2023 Download this Press Release as a PDF IngenOx Therapeutics, an Oxford-based biopharmaceutical company, announced that its Chief Medical Officer, Prof. David Kerr had published a review on the use of diagnostic biomarkers to personalise…